BY MARKETWIRE
-
Compounder files lawsuit against Novo Nordisk and Eli Lilly
Neither Novo Nordisk nor Eli Lilly has responded to Bloomberg News’ request for comment on the lawsuit.
-
FDA requests removal of suicide warning from GLP-1 Drugs
This follows wellness authorities located no boosted threat in an evaluation.
-
Demant, GN and WS Audiology gained market share among US veterans in December
On the whole, sales of listening device and cordless hearing systems increased by 2.9%.
-
Wegovy tablet launch may be one of Novo Nordisk’s biggest, says bank
” In our sight, a Zepbound-like launch is not impractical,” Danske Financial institution states regarding the launch of Novo Nordisk’s weight problems tablet.
-
Novo Nordisk: Up to 1.5 million patients users on copies in the USA
Mike Doustdar stated on monday that as much as 1.5 million American individuals make use of duplicate medications from “compounders” of GLP-1 drug.
-
Nvidia and Eli Lilly collaborate on AI laboratory
Drug gigantic Eli Lilly has actually partnered with chip gigantic Nvidia on a brand-new lab.
-
Danske Bank: Coloplast’s Kerecis may gain market shares following new pricing policy in the US
Coloplast’s Kerecis is positioned to acquire market shares in the United States. New rates plan supplies greater aids than the ordinary cost for injury treatment items.
-
Reduced import of pharmaceuticals leads to smallest trade deficit in the US since 2009
According to Bloomberg, the decrease in the profession deficiency is specifically because of a decrease in the import of drugs.
-
Chinese drug manufacturers signed record-breaking licensing deals in 2025
Loads of billion-dollar bargains in between Chinese companies and worldwide pharma titans drove the document high.
-
Eli Lilly completes billion-dollar acquisition of US biotech company
Eli Lilly announced the agreement Wednesday following the close of trading in the US.
